Recent studies have shown that plasma biomarkers, such as Aβ42/Aβ40 ratios, p-Tau, and NfL, can predict cognitive decline and the transition to AD in cognitively unimpaired individuals. The gene discussed is MAPT; the disease is Alzheimer disease.